TerminatedPhase 2NCT00840827

Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic Syndromes

Studying Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Last synced from ClinicalTrials.gov April 1, 2026

ℹ

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.

Report missing data

Key facts

Sponsor: Weill Medical College of Cornell University
Principal Investigator: Eric Feldman, MD
Weill Medical College of Cornell University
Intervention: lenalidomide(drug)
Enrollment: 6 target
Eligibility: 18 years · All sexes
Timeline: 2008 – 2010

Study locations (1)

Weill Cornell Medical College, New York, New York, United States

Collaborators

Celgene

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT00840827 on ClinicalTrials.gov

Other trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality

Additional recruiting or active studies for the same condition.

ACTIVE NOT RECRUITINGPHASE3NCT03223961
A Trial Testing Early vs Late Onset of EPO Alfa Treatment in Lower Risk MDS
Groupe Francophone des Myelodysplasies

See all trials for Myelodysplastic syndrome associated with isolated del(5q) chromosome abnormality →

← Back to all trials